Results 91 to 100 of about 5,648 (180)

Targeting of CD28 and CD38 as a potential novel therapeutic strategy for peripheral T-cell lymphomas. [PDF]

Sci Rep
Dupuy A, Pelletier L, Beldi-Ferchiou A, Poullot E, Tari G, Naudet J, Lemonnier F, Fataccioli V, Gupta B, Kim PS, Bisht K, Wang H, Van de Velde H, Gaulard P, Ortonne N.   +14 more
europepmc   +1 more source

Cardiac Involvement as First Manifestation of Peripheral T-Cell Not Otherwise Specified Lymphoma. [PDF]

Eur J Case Rep Intern Med
Awamleh García P, Monguió Santín ME, López Martínez C, Hernández Muñiz S, de la Serna Real de Asúa M, Alonso Trillo R, Delgado Trillo MI.   +6 more
europepmc   +1 more source

A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma. [PDF]

Blood Adv
Gordon MJ, Miljkovic MD, Milhon P, Lakhotia R, Melani C, Johnson K, Bryant B, Pittaluga S, Jaffe ES, Conlon K, Staudt LM, Wilson WH, Roschewski M, Ng S.   +13 more
europepmc   +1 more source

Synergistic adverse prognostic impact of CD30 and Epstein-Barr virus in peripheral T-cell lymphoma: CD30 identifies a high-risk subgroup in Epstein-Barr virus-encoded RNA -positive patients. [PDF]

Ann Hematol
Chen ZT, Huang L, Zhang XD, Wang N, Jiang XM, Wei XJ, Zhang H, Guo HG, Lin CD, Chen FL, Liu SC, Liang ZL, Li WY.   +12 more
europepmc   +1 more source

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26). [PDF]

Blood Cancer J
Wei J, Cai Q, Zhang L, Zou L, Li Z, Zhou K, Wu H, Qiu L, Su L, Ding K, Zhou H, Yu L, Li F, Li W, Lin L, Xiao Q, Wang E, Jing H, Zheng M, Zhang H, Gao Y, Gao D, Chen L, Jin J.   +23 more
europepmc   +1 more source

Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database. [PDF]

J Pharm Health Care Sci
Takatsu N, Matsumoto J, Oka Y, Sakai T, Iwata N, Higashionna T, Takeda T, Hamano H, Zamami Y.   +8 more
europepmc   +1 more source

From Cell Lines to Avatars: Charting the Future of Preclinical Modeling in T-Cell Malignancies. [PDF]

Cells
Piccaluga PP, Cimmino L, Tsekhovska V, Cimatti P, Innocenti C, Seidenari S, Calafato G, Di Paola FJ, Tallini G.   +8 more
europepmc   +1 more source

Can baseline red blood cell distribution width predict outcomes in peripheral T-cell lymphoma patients? [PDF]

Ann Hematol
Lan Y, Zhao Y, Sun J, Zhou, Wang J, Zheng X, Shi Y, Meng H, Wei J, Yang C, Yu W, Jin J, Tong H, Xie W.   +13 more
europepmc   +1 more source

Successful Treatment of Peripheral T-cell Lymphoma Not Otherwise Specified in Bilateral Subconjunctiva: A Case Report. [PDF]

Cureus
Ota H, Arihiro K, Mihara K, Chikama TI.
europepmc   +1 more source

Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party. [PDF]

Hemasphere
Shumilov E, Ngoya M, Berning P, Khvedelidze I, Serroukh Y, Wondergem M, Cwynarski K, Thurner L, Wahlin BE, Zeiser R, Hazenberg C, Nicholson E, Remenyi P, Netelenbos T, Lenhoff S, Tournilhac O, Wilson K, Ho A, Lenz G, Wulf G, Glass B, Dreger P, Sureda A, Damaj G, Bazarbachi A, Schmitz N.   +25 more
europepmc   +1 more source